Korea's Celltrion Eyes Eastern Bloc For Biosimilar Expansion
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korean biopharmaceutical firm Celltrion posted record high profits in the third quarter, thanks to continued brisk shipment of its biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to countries in South America, the Middles East and Asia
You may also be interested in...
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
SEOUL - South Korea's biosimilar front-runner Celltrion said it will push back the anticipated launch of biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to early 2012, instead of the original plan for a launch in the second half of 2011
Celltrion Pushes Back Launch Of Roche And Johnson & Johnson Biosimilars To 2012
SEOUL - South Korea's biosimilar front-runner Celltrion said it will push back the anticipated launch of biosimilars of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to early 2012, instead of the original plan for a launch in the second half of 2011
Biosimilars Aid Korea's Celltrion To Post Record Sales And Profit In FY 2010
SEOUL - South Korea's biosimilar front-runner Celltrion reported an all-time record high performance for sales and net profit in 2010, mainly from sales of its biosimilars of Roche's breast cancer agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis drug Remicade (infliximab) to countries in South America, the Middle East and Asia